Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia

Publisher： Karger

E-ISSN： 1421-9662|127|4|228-234

ISSN： 0001-5792

Source： Acta Haematologica, Vol.127, Iss.4, 2012-04, pp. : 228-234

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute

By  

Acta Haematologica, Vol. 128, Iss. 4, 2012-08 ,pp. : 223-232

Karger

Access to resources Recommend Favorite

Rapid reduction in BCR‐ABL1 transcript predicts deep molecular response in dasatinib‐treated chronic‐phase chronic myeloid leukaemia patients

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 27-35

John Wiley & Sons Inc

Access to resources Recommend Favorite

Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia Patients after Imatinib Mesylate and Dasatinib Therapy

By  

Acta Haematologica, Vol. 133, Iss. 4, 2015-02 ,pp. : 354-364

Karger

Access to resources Recommend Favorite

Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4284-4289

John Wiley & Sons Inc

Access to resources Recommend Favorite